Figure 5. Overall survival in a phase II trial of ofatumumab as single-agent [19].
A) Overall survival in fludarabine- and alemtuzumab refractory patients (FA-ref). B) Overall survival in fludarabine-refractory patients with bulky disease (BF-ref)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.